{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:02:34Z","timestamp":1790229754451,"version":"4.1.0"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Severe potential drug-drug interactions (pDDIs) in intensive care unit (ICU) patients remain insufficiently characterized. This study investigated the incidence, patterns, burden, and associated factors of severe pDDIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center retrospective cohort included ICU admissions from January 2023 through December 2024 for adults aged \u226518\u00a0years who received \u22652 eligible systemic medications administered orally or intravenously. Category D and X pDDIs were identified with Lexi-Interact (Lexidrug, UpToDate) using confirmed administration records. Logistic and ordinal logistic regression were performed to evaluate severe-pDDI occurrence (\u22651) and admission-level burden (0, 1\u20132, or \u22653).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1,170 ICU admissions were included, involving 26,627 medication administrations. 64.44% were male and 55.38% received mechanical ventilation support. The most common implicated pharmacological group was alimentary-tract and metabolism agents, while ambroxol and glutathione emerged as the top two individual drugs. Among 1,170 ICU admissions, 1,092 (93.33%) exhibited pDDIs, and 769 (65.73%) experienced at least one category D or X pDDI. The 2,704 severe pDDIs comprised 1,681 (62.17%) category D and 1,023 (37.83%) category X events, yielding 231.1 pDDIs per 100 admissions and 101.6 pDDIs per 1,000 medication administrations. Nervous-system agents predominated; butorphanol [948\/5,408 ingredient involvements (17.53%)] and dexmedetomidine [824\/5,408 (15.24%)] were most frequently implicated. Butorphanol\u2013dexmedetomidine [335\/2,704 events (12.39%)] and noscapine\u2013chlorphenamine [176\/2,704 (6.51%)] were the leading category D and X pairs, respectively. Additive pharmacodynamic central nervous system depression predominated. Mechanical ventilation and medication count were the strongest adjusted correlates of severe-pDDI occurrence and burden, while baseline variables (sex, APACHE II score) lost significance after adjusting for ICU process variables. These associations remained materially unchanged after excluding 29 readmission encounters. In an exploratory review of 50 severe-pDDI episodes, 32 (64.0%) had temporally associated clinical signs or events documented and 29 (58.0%) had a documented management action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Category D or X pDDI alerts were frequent, primarily driven by pharmacodynamic additive central nervous system depression from sedative\u2013analgesic combinations. Treatment intensity rather than baseline characteristics was associated with severe-pDDI exposure. Regional ICU-tailored surveillance and pharmacist-integrated medication management may facilitate identification of high-risk combinations, although specific drug pairs require validation across different healthcare settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1920401","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:37:30Z","timestamp":1790228250000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence, burden, and associated factors of severe potential drug\u2013drug interactions in intensive care unit patients: a real-world retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Huaqiao","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Jinshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Jinshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nursing, Jinshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Jinshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jinshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqun","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jinshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nursing, Jinshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Jinshan Hospital, Fudan University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1515\/dmpt-2020-0114","article-title":"Potential drug-drug interactions in ICU patients: a retrospective study","volume":"35","author":"Ali","year":"2020","journal-title":"Drug Metabolism Drug Interact."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s11096-017-0525-4","article-title":"Prevalence and nature of potential drug\u2013drug interactions among kidney transplant patients in a German intensive care unit","volume":"39","author":"Amkreutz","year":"2017","journal-title":"Int. J. Clin. Pharm."},{"key":"B3","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1177\/00185787231153613","article-title":"Frequency, predictors, and outcomes of the potential drug-drug interactions in the ICUs of teaching hospitals in Ardabil, Northwest of Iran during 2019-2020","volume":"58","author":"Arab","year":"2023","journal-title":"Hosp. Pharm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1111\/jcpt.13784","article-title":"The effect of the clinical pharmacist in minimizing drug-related problems and related costs in the intensive care unit in Turkey: a non-randomized controlled study","volume":"47","author":"Ayhan","year":"2022","journal-title":"J. Clin. Pharm. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/MS9.0000000000001355","article-title":"Assessment of frequency and types of drug interactions in intensive care units: a cross-sectional study","volume":"86","author":"Baghaei","year":"2023","journal-title":"Ann. Med. and Surg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jcrc.2020.11.020","article-title":"Clinically relevant potential drug-drug interactions in intensive care patients: a large retrospective observational multicenter study","volume":"62","author":"Bakker","year":"2021","journal-title":"J. Crit. Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/jcph.2020","article-title":"Heterogeneity in the identification of potential drug-drug interactions in the intensive care unit: a systematic review, critical appraisal, and reporting recommendations","volume":"62","author":"Bakker","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/s0140-6736(23)02465-0","article-title":"The effect of computerised decision support alerts tailored to intensive care on the administration of high-risk drug combinations, and their monitoring: a cluster randomised stepped-wedge trial","volume":"403","author":"Bakker","year":"2024","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13613-015-0086-4","article-title":"Important drug classes associated with potential drug\u2013drug interactions in critically ill patients: highlights for cardiothoracic intensivists","volume":"5","author":"Baniasadi","year":"2015","journal-title":"Ann. Intensive Care"},{"key":"B10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1080\/03602532.2020.1859528","article-title":"CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation","volume":"53","author":"Barrangou-Poueys-Darlas","year":"2021","journal-title":"Drug Metab. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/pharmaceutics14040789","article-title":"Magnitude of drug\u2013drug interactions in special populations","volume":"14","author":"Bettonte","year":"2022","journal-title":"Pharmaceutics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e079789","DOI":"10.1136\/bmj-2024-079789","article-title":"Management of pain and sedation in the intensive care unit","volume":"387","author":"Boncyk","year":"2024","journal-title":"Bmj"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e0246754","DOI":"10.1371\/journal.pone.0246754","article-title":"Clinical significance of potential drug\u2013drug interactions in a pediatric intensive care unit: a single-center retrospective study","volume":"16","author":"Chen","year":"2021","journal-title":"Plos One"},{"key":"B14","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.pedneo.2020.10.006","article-title":"Drug\u2013drug interactions in neonatal intensive care: a prospective cohort study","volume":"62","author":"Costa","year":"2021","journal-title":"Pediatr. and Neonatol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.26355\/eurrev_202109_26798","article-title":"Evaluation of potential drug-drug interactions in intensive care unit","volume":"25","author":"Dagdelen","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"965441","DOI":"10.3389\/fphar.2022.965441","article-title":"Efficacy of dexmedetomidine versus midazolam when combined with butorphanol for sedation and analgesia during burn dressing changes: a randomized clinical trial","volume":"13","author":"Ding","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s40264-019-00829-y","article-title":"Evaluation of potential drug\u2013drug interactions in adults in the intensive care unit: a systematic review and meta-analysis","volume":"42","author":"Grace","year":"2019","journal-title":"Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/17425255.2025.2511961","article-title":"A comparative study on the consistency of different decision support software systems from the perspective of potential drug\u2013drug interactions in intensive care unit patients","volume":"21","author":"Han","year":"2025","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"7108","DOI":"10.26355\/eurrev_202111_27264","article-title":"Potential drug-drug interactions in University Hospital Medical Intensive Care Unit patients in Turkey","volume":"25","author":"Jafarova Demirkapu","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"9396","DOI":"10.26355\/eurrev_202310_33967","article-title":"Prevalence of potential drug-drug interactions among intensive care unit patients receiving linezolid: a cross-sectional study","volume":"27","author":"Jiang","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4274\/tybd.galenos.2024.15045","article-title":"Potential drug-drug interaction detection using the UpToDate Mobile application in intensive care: a retrospective, observational study","volume":"23","author":"Kayhan","year":"2025","journal-title":"Turkish J. Intensive Care"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3390\/pharmaceutics12121201","article-title":"Drug-drug interactions involving intestinal and hepatic CYP1A enzymes","volume":"12","author":"Klomp","year":"2020","journal-title":"Pharmaceutics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/bcp.15882","article-title":"Adverse drug events caused by three high\u2010risk drug\u2013drug interactions in patients admitted to intensive care units: a multicentre retrospective observational study","volume":"90","author":"Klopotowska","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.3390\/antibiotics10111330","article-title":"Clinically relevant interactions with anti-infectives on intensive care units\u2014A multicenter Delphi study","volume":"10","author":"Koeck","year":"2021","journal-title":"Antibiot. (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1097\/CCM.0000000000006574","article-title":"A focused update to the Clinical Practice Guidelines for the prevention and management of pain, anxiety, agitation\/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU","volume":"53","author":"Lewis","year":"2025","journal-title":"Crit. Care Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"555407","DOI":"10.3389\/fphar.2020.555407","article-title":"Severe potential drug-drug interactions and the increased length of stay of children in intensive care unit","volume":"11","author":"Lima","year":"2020","journal-title":"Front. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/pharmaceutics13020266","article-title":"Drug\u2013drug interactions in elderly patients with potentially inappropriate medications in primary care, nursing home and hospital settings: a systematic review and a preliminary study","volume":"13","author":"Mathilde","year":"2021","journal-title":"Pharmaceutics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40262-023-01213-x","article-title":"Pharmacokinetic alterations associated with critical illness","volume":"62","author":"Morales Castro","year":"2023","journal-title":"Clin. Pharmacokinetics"},{"key":"B29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/pharmacy10040096","article-title":"Drug utilization and potential drug-drug interactions within an intensive care unit at a university tertiary care hospital in Egypt","volume":"10","author":"Obeid","year":"2022","journal-title":"Pharmacy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1473719","DOI":"10.3389\/fmed.2024.1473719","article-title":"Clinical pharmacist interventions in nutrition-and drug-related problems in critically ill patients with renal dysfunction: a non-randomized controlled study","volume":"11","author":"\u00d6zgan","year":"2024","journal-title":"Front. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1186\/s12913-024-12015-7","article-title":"Pharmacist-led interventions for vascular surgery patients: a prospective study on reducing drug-related problems","volume":"24","author":"Porubcova","year":"2024","journal-title":"BMC Health Serv. Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s00134-025-07938-6","article-title":"Understanding and mitigating medication errors associated with patient harm in adult intensive care units: a scoping review","volume":"51","author":"Puxty","year":"2025","journal-title":"Intensive Care Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"290","DOI":"10.7399\/fh.13180","article-title":"Drug-drug interactions in an intensive care unit and comparison of updates in two databases","volume":"46","author":"Riera","year":"2022","journal-title":"Farm Hosp."},{"key":"B34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/phar.1395","article-title":"Analysis of potential drug-drug interactions in medical intensive care unit patients","volume":"34","author":"Uijtendaal","year":"2014","journal-title":"Pharmacotherapy"},{"key":"B35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40360-022-00582-6","article-title":"Prevalence of potential drug \u2212 drug interactions in the cardiothoracic intensive care unit patients in a Chinese tertiary care teaching hospital","volume":"23","author":"Wang","year":"2022","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1038\/s41598-026-35071-x","article-title":"Optimizing butorphanol-dexmedetomidine dosing for managing catheter-related bladder discomfort post-anesthesia: a randomized trial","volume":"16","author":"Wang","year":"2026","journal-title":"Sci. Rep."},{"key":"B37","unstructured":"World Health Organization ATC\/DDD index\n          \n          \n          2025"},{"key":"B38","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40360-025-00925-z","article-title":"Prevalence and clinical significance of potential drug-drug interactions of antimicrobials in intensive care unit patients: a retrospective study","volume":"26","author":"Xu","year":"2025","journal-title":"BMC Pharmacol. Toxicol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1308260","DOI":"10.3389\/fphar.2024.1308260","article-title":"Prevalence and clinical significance of potential drug-drug interactions among lung transplant patients","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1920401\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:37:33Z","timestamp":1790228253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1920401\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":39,"alternative-id":["10.3389\/fphar.2026.1920401"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1920401","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1920401"}}